A 100% drug tariff becomes a sorting machine on September 29

A Section 232 proclamation issued in April 2026 imposed a 100% duty on imported patented pharmaceuticals and the active ingredients that go into them, structured in tiers. The default rate is 100%. A company with a Commerce Department-approved onshoring plan pays 20%. A company that signs both an onshoring agreement with Commerce and a most-favoured-nation pricing agreement with the Department of Health and Human Services pays nothing at all, through January 20, 2029.

The 100% rate took effect on July 31, 2026 for the seventeen large firms named in the proclamation’s Annex III, and applies to all other companies from September 29, 2026 — a staggered window of 120 days for the larger firms and 180 days for the smaller ones. Generic drugs and biosimilars are excluded for now, though the proclamation directs Commerce to review within one year whether to extend the tariff to them.

On August 31, 2026 the administration announced that nine further manufacturers — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB — had agreed to most-favoured-nation pricing for Medicaid, bringing the total number of companies inside the programme to twenty-six. Announced US manufacturing commitments across the industry now exceed $480 billion across 22 sites.

Opportunity

Almost all the coverage treats this as a drug-pricing story and asks whether patients save money. Read structurally it is something else. A company paying zero while a direct competitor pays one hundred percent on the same imported molecule is holding one of the largest cost advantages ever created by a single administrative act, and it is contractually fixed until January 2029.

Hypothesis: the market appears to be scoring these agreements as concessions — a company giving up price to Medicaid — when for a firm with modest Medicaid exposure and heavy import exposure the arithmetic may run strongly the other way, making the deal closer to cheaply purchased tariff immunity than to a price cut. Nobody seems to have worked that trade-off company by company.

The second and less examined side is the losers: on September 29 the full rate simply arrives for every remaining importer of patented product, and the list of who is not inside the programme has not been assembled anywhere I can find. That absence is itself the opportunity, because it is a finite, researchable list with a hard date attached.

How it could play out

The deadline passes and a set of mid-sized importers discover their US gross margin has been halved on products they cannot reprice mid-contract. Some capitulate into agreements on worse terms; some exit US launches; some become acquisition targets for companies that already hold exemptions. Meanwhile the signers must actually build the plants they promised, which means real orders eventually landing on bioprocessing, cleanroom and fill-finish suppliers — and if Commerce extends the tariff to generics inside the review year, the same sorting happens again to a much larger and far more fragile supply chain.

Questions worth asking

• Who is not on the list? Building the roster of listed mid-cap and specialty pharmaceutical companies that import patented product into the United States and hold neither a pricing nor an onshoring agreement is the piece of work that decides this idea.
• What does a most-favoured-nation Medicaid price actually cost a given company, set against a 100% tariff avoided? For some the exchange is plainly favourable and the disclosure to test it exists in their filings.
• The exemption runs to January 20, 2029 — the end of a presidential term. Have the signers bought protection that lasts exactly as long as the administration that granted it, and is that priced into anything?
• If Commerce extends the tariff to generics within its review year, which companies are structurally unable to survive it, and does that make the generic supply chain a policy short rather than a value long?
• Where the tariff does bite, who absorbs the cost? Hospitals and health systems buying physician-administered drugs cannot reprice inside a contract year, and that exposure sits well outside the pharmaceutical sector.

Where to look

• Teva Pharmaceuticals, Sun Pharma, CSL, UCB, Astellas Pharma, Alcon, BridgeBio, Kyowa Kirin and BeOne Medicines — the newly signed group, each now holding a tariff position their unsigned peers do not
• Eli Lilly, Pfizer and Johnson & Johnson — already inside the regime and furthest along on American plants
• Thermo Fisher Scientific, Danaher, Sartorius, Repligen and West Pharmaceutical Services — the equipment, consumables and containment suppliers that any genuine onshoring has to buy from
• hospital operators and drug distributors, on the receiving end of whatever cost is not exempted

Thesis check

The strength is that the mechanism is statutory, dated and extreme — a hundred-point tariff differential between two competitors selling the same class of product has to show up in somebody’s margins. The real constraints are three: this administration’s tariff deadlines have a poor record of arriving unamended, generics and biosimilars are excluded so the affected revenue pool is far narrower than the headline rate suggests, and the companies most brutally exposed may turn out to be private or listed abroad, leaving a correct thesis with nothing clean to express it through.

Sources

White House proclamation, Apr 2026 · Crowell & Moring, 2026 · White House fact sheet, Aug 31 2026 · STAT, Sept 1 2026